Taken together, since direct anti-HER3 therapeutic options are limited (because of its lack of a tyrosine kinase domain), we suggest that JAM-A represents a novel target meriting investigation to reduce compensatory HER3 expression/signaling in cancer patients resistant to HER2-targeted therapies. Here, ERBB2 is linked to cancer.